1 results match your criteria: "Shenzhen HospitalSouthern Medical University[Affiliation]"
PD-1 inhibitor combined with chemotherapy or lenvatinib in advanced gallbladder cancer: a retrospective comparative study.
BMC Gastroenterol
February 2025
Department of Hepatobiliary Surgery, Shenzhen HospitalSouthern Medical University, ShenZhen, China.
Background: Gallbladder cancer (GBC) is a refractory primary cancer. Some GBC patients are prone to recurrence even after surgical resection. In such cases, chemotherapy is the most common non-surgical treatment.
View Article and Find Full Text PDF